Patents Examined by Jody Karol
  • Patent number: 10085958
    Abstract: Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY™ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: October 2, 2018
    Assignee: BAUSCH & LOMB PHARMA HOLDINGS CORP.
    Inventors: Angel Padilla, George Baklayan
  • Patent number: 10046000
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 14, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Julia B. Zella, Margaret Clagett-Dame
  • Patent number: 10022315
    Abstract: The cosmetic or non-therapeutic use of an oral composition for reinforcing an individual's skin tolerance to topical administration of a retinoid compound, the oral composition having at least one carotenoid, at least one phytoestrogen and vitamin C. A cosmetic or non-therapeutic process for increasing an individual's skin tolerance to topical administration of a retinoid compound, having at least one step of oral administration to the individual of an oral composition having at least one carotenoid, at least one phytoestrogen and vitamin C. A set for simultaneous, separate or sequential administration, the set having a first cosmetic composition for topical application having, in a physiologically acceptable medium, at least one effective amount of a retinoid compound, and a second composition for oral administration, for reinforcing the skin tolerance of the individual treated with the first composition, the second composition having at least one carotenoid, at least one phytoestrogen and vitamin C.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: July 17, 2018
    Assignee: LABORATOIRES INNEOV
    Inventor: Nathalie Piccardi
  • Patent number: 10011610
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: July 3, 2018
    Assignee: Eli Lilly and Company
    Inventors: David Michael Remick, Simon James Richards, Adam Jan Sanderson
  • Patent number: 10010525
    Abstract: The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: July 3, 2018
    Assignee: The Regents of the University of California
    Inventor: Robert J. Brosnan
  • Patent number: 10005781
    Abstract: Pyrazolopyrimidone and pyrrolotriazone derivatives, methods of preparation thereof, and pharmaceutical uses thereof are described. Specifically, pyrazolopyrimidone and pyrrolotriazone derivatives represented by the general formula (I) and pharmaceutically acceptable salts thereof are described. The pyrazolopyrimidone and pyrrolotriazone derivatives are useful as gonadotropin releasing hormone (GnRH) antagonists, such as for therapeutic agents for endometriosis. The definitions of the substituents in the general formula (I) are the same as the definitions in the specification.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: June 26, 2018
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Hejun Lu, Piaoyang Sun, Bin Gui, Qing Dong
  • Patent number: 9999601
    Abstract: The presently claimed and disclosed invention(s) provides a therapeutically effective composition and method of inhibiting nerve cell transmission. In a preferred embodiment of the presently claimed and disclosed invention(s), the treatment of neuropathic pain utilizing terpene compounds isolated from plant essential oils or manufactured synthetically is detailed. These compounds, such as geraniol and citronellol, as well as chemical analogs thereof, used in combination or individually, can be used alone or in a composition with a pharmaceutically acceptable carrier in a suitable dosage form.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: June 19, 2018
    Assignee: NEUROQUEST INC.
    Inventors: Alexander McLellan, Frank Greenway
  • Patent number: 9999602
    Abstract: A composition is provided comprising: (i) menthol, and (ii) a carrier comprising a digestible edible oil, wherein said digestible edible oil is one that provides a composition which is a liquid at 20° C. after rising to that temperature from a lower temperature at which the oil was previously semisolid. The preferred edible oil is a medium-chain triglyceride oil, wherein the level of menthol in the composition is between 1-50% by total weight, so as to provide an menthol application rate of between 5 and 20 mg of menthol, and most preferably, about 10 mg menthol, in a single droplet of the composition. The composition can also include additional added vitamins and essential oils. A liquid method for administering menthol is provided.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: June 19, 2018
    Assignee: DDROPS COMPANY
    Inventors: Simon George Vieth, Chris James Temovsky, Reinhold William Vieth
  • Patent number: 9981970
    Abstract: Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, wherein X is —C(?O) or —S(O)2—, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: May 29, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Pengcheng Patrick Shao, Arto K. Krikorian, Petr Vachal
  • Patent number: 9975879
    Abstract: Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in it etiology.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: May 22, 2018
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Magid Abou-Gharbia, Wayne E. Childers, Rogelio L. Martinez, Mercy M. Ramanjulu, Benjamin E. Blass
  • Patent number: 9949919
    Abstract: Described herein are methods and compositions for increasing the efficacy and decreasing the irritancy of topical formulations of hydroquinone.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: April 24, 2018
    Assignee: SHAMROC, INC.
    Inventors: Ronald M. Gurge, Mark W. Trumbore, Nupoor Devrajbhai Hirani
  • Patent number: 9944632
    Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of estrogen-related diseases and conditions.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: April 17, 2018
    Assignee: Accutar Biotechnology Inc.
    Inventors: Jie Fan, Ke Liu
  • Patent number: 9937145
    Abstract: The present invention relates to a pharmaceutical composition for treating or preventing epilepsy containing a sulfamate derivative compound and/or pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the present invention relates to a method for treatment or prevention epilepsy comprising administering a sulfamate derivative compound in a pharmaceutically effective amount to a subject in need of treatment or prevention of epilepsy.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: April 10, 2018
    Assignee: Bio-Pharm Solutions Co., Ltd.
    Inventor: Yong Moon Choi
  • Patent number: 9931293
    Abstract: The present invention relates to a cosmetic composition comprising (a) about 10% to about 20% by weight, based upon the total weight of the composition of a film forming agent; (b) about 1% to about 25% by weight, based upon the total weight of the composition of a particulate material; (c) two or more thickening agents; and (d) water. When applied to the skin, the composition allows for immediate tightening of the skin while decreasing the visibility of fine lines and deep wrinkles.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: April 3, 2018
    Assignee: L'Oreal
    Inventors: Sabina Gosto, Patricia Brieva, Donna McCann
  • Patent number: 9932340
    Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: April 3, 2018
    Assignee: AbbVie Inc.
    Inventors: Yujia Dai, William McClellan, Mike Michaelides, Ramzi Sweis, Noel Wilson, Justin Dietrich
  • Patent number: 9925266
    Abstract: The invention related to a gelling formulation including calcium gluconate in solution in water and a poloaxmer and to the use thereof in the treatment of hydrofluoric acid burns.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: March 27, 2018
    Assignee: Assistance Publique—Hopitaux de Paris
    Inventors: Vincent Boudy, Sandrine Graff De Faget, Marie-Caroline Husson, Imane Boucenna, Laurent Royon, Pierre Colinart
  • Patent number: 9918472
    Abstract: The invention provides an animal repellent containing, as an active ingredient, a compound having an odor innately inducing fear in animals, which is free from acclimation of animals to the aforementioned odor. The active ingredient is at least one kind selected from a heterocyclic compound represented by the formula (1): wherein ring A is a 3- to 7-membered heterocycle containing at least one hetero atom selected from a nitrogen atom, a sulfur atom and an oxygen atom, and R1 and R2 are each independently hydrogen, a halogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group, an acyl group, an optionally esterified carboxyl group, an optionally substituted thiol group, an optionally substituted amino group or an oxo group, or a salt thereof, a chain sulfide compound and alkyl isothiocyanate.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: March 20, 2018
    Assignee: Scent Science International Inc.
    Inventors: Ko Kobayakawa, Reiko Kobayakawa
  • Patent number: 9907776
    Abstract: The present invention relates to a composition for preventing or treating a psychiatric disorder comprising a phenyl carbamate compound and a method for preventing or treating a psychiatric disorder therewith. The present invention provides anti-anxiety activity and protections against seizure and bipolar disorder, such that it may be effectively used for preventing or treating various psychiatric disorders related to mood disorder or resulting convulsion.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 6, 2018
    Assignee: Bio-Pharm Solutions, Co., Ltd.
    Inventor: Yong Moon Choi
  • Patent number: 9896435
    Abstract: Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B and the NH—C(?X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: February 20, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Barbara J. Brandhuber, Timothy Kercher, Gabrielle R. Kolakowski, Shannon L. Winski
  • Patent number: 9889111
    Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a ?-(arylsulfonyl)alkylnitrile compound, or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering an ?-(arylsulfonyl)alkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: February 13, 2018
    Assignee: OLATEC THERAPEUTICS LLC
    Inventors: Joseph St. Laurent, Gerald S. Jones, David M. Bresse